These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23152355)

  • 1. Secondary bronchiolitis obliterans organizing pneumonia during treatment of chronic hepatitis C: role of pegylated interferon alfa-2a.
    Martins RS; Machado JA; Teixeira R
    Rev Soc Bras Med Trop; 2012 Oct; 45(5):655-6. PubMed ID: 23152355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of bronchiolitis obliterans organizing pneumonia during standard treatment of hepatitis C with Peg-IFNα2b.
    Chung E; Park K; Kim JH; Han NI; Lee YS; Bae SH; Park CH
    Korean J Intern Med; 2017 Nov; 32(6):1098-1100. PubMed ID: 28823117
    [No Abstract]   [Full Text] [Related]  

  • 3. [Organizing pneumonia associated with the use of pegylated interferon alfa].
    Trullas Vila JC; Padilla López DR; Bisbe Company V; Soler Simón S; Cortés Hausmann P; Bisbe Company J
    Arch Bronconeumol; 2008 Mar; 44(3):173-4. PubMed ID: 18361890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary complications of treatment with pegylated interferon for hepatitis C infection-two case reports.
    Hegade VS; Sood R; Saralaya D; Moreea S
    Ann Hepatol; 2013; 12(4):629-33. PubMed ID: 23813142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
    Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS
    Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial pneumonitis after treatment for hepatitis C virus infection.
    Botnaru V; Munteanu O; Rusu D
    Pneumologia; 2015; 64(1):46-50. PubMed ID: 26016056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-related bronchiolitis obliterans organizing pneumonia.
    Ogata K; Koga T; Yagawa K
    Chest; 1994 Aug; 106(2):612-3. PubMed ID: 7774350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
    Slim J; Afridi MS
    Infect Dis Clin North Am; 2012 Dec; 26(4):917-29. PubMed ID: 23083824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Halász T; Farkas A; Tolvaj G; Horváth G
    Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
    Foster GR; Zeuzem S; Pianko S; Sarin SK; Piratvisuth T; Shah S; Andreone P; Sood A; Chuang WL; Lee CM; George J; Gould M; Flisiak R; Jacobson IM; Komolmit P; Thongsawat S; Tanwandee T; Rasenack J; Sola R; Messina I; Yin Y; Cammarata S; Feutren G; Brown KK
    J Viral Hepat; 2013 Apr; 20(4):e115-23. PubMed ID: 23490379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials.
    Chou R; Carson S; Chan BK
    J Viral Hepat; 2008 Aug; 15(8):551-70. PubMed ID: 18482285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection.
    Tsilika K; Tran A; Trucchi R; Pop S; Anty R; Cardot-Leccia N; Lacour JP; Ortonne JP; Passeron T
    JAMA Dermatol; 2013 Jun; 149(6):675-7. PubMed ID: 23553009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of chronic hepatitis C patient of myocardial ischemia accompanied with interstitial pneumonia induced by pegylated interferon alpha-2a.
    Qu C; Zheng Z; Liu W; Jiao J; Zhu J
    Int J Clin Exp Pathol; 2014; 7(8):5232-5. PubMed ID: 25197402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin.
    Ennaifer R; Cheikh M; Romdhane H; Hefaiedh R; Ben Nejma H; Bel Hadj N
    Tunis Med; 2014 Jan; 92(1):42-3. PubMed ID: 24879173
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin: case report and literature review].
    Cacopardo B; Pinzone MR; Nunnari G
    Infez Med; 2013 Mar; 21(1):40-44. PubMed ID: 23524900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Penile paraffinoma developing during treatment with pegylated interferon alfa-2a for chronic hepatitis C virus infection.
    Bachmeyer C; Moguelet P; Gombeaud T; Sbidian E; Aractingi S
    Arch Dermatol; 2011 Oct; 147(10):1232-3. PubMed ID: 22006152
    [No Abstract]   [Full Text] [Related]  

  • 19. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.